Douglas A Tremblay - Hematology-Oncology

Biography

Specialties

Hematology-Oncology

Douglas Tremblay, MD is an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai. Dr. Tremblay completed fellowship and residency training at Mount Sinai where he served as both Chief Fellow and Chief Resident. His clinical and translational research focus is on hematologic malignancies, particularly myelodysplastic/myeloproliferative overlap syndromes including chronic myelomonocytic leukemia (CMML) as well as myeloproliferative neoplasms (MPNs) and acute myeloid leukemia. Dr. Tremblay is the Principal Investigator (PI) on numerous investigator-initiated and industry sponsored early and late phase clinical trials in myeloid neoplasms. Additionally, he is a participant in the American Society of Hematology Clinical Research Training Institute and holds multiple administrative roles at Mount Sinai.

Clinical Focus

Acute Lymphoid Leukemia
Acute Myeloid Leukemia
Anemia
Chronic Myelocytic Leukemia
Essential Thrombocythemia
Leukemia
Myelodysplastic Syndromes
Myelofibrosis
Myeloproliferative Disorders
Myeloproliferative Neoplasms (MPN)
Polycythemia Vera
Primary Polycythemia

Douglas Tremblay, MD is an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai. Dr. Tremblay completed fellowship and residency training at Mount Sinai where he served as both Chief Fellow and Chief Resident. His clinical and translational research focus is on hematologic malignancies, particularly myelodysplastic/myeloproliferative overlap syndromes including chronic myelomonocytic leukemia (CMML) as well as myeloproliferative neoplasms (MPNs) and acute myeloid leukemia. Dr. Tremblay is the Principal Investigator (PI) on numerous investigator-initiated and industry sponsored early and late phase clinical trials in myeloid neoplasms. Additionally, he is a participant in the American Society of Hematology Clinical Research Training Institute and holds multiple administrative roles at Mount Sinai.

Clinical Focus

Acute Lymphoid Leukemia
Acute Myeloid Leukemia
Anemia
Chronic Myelocytic Leukemia
Essential Thrombocythemia
Leukemia
Myelodysplastic Syndromes
Myelofibrosis
Myeloproliferative Disorders
Myeloproliferative Neoplasms (MPN)
Polycythemia Vera
Primary Polycythemia

Education

MD, Albert Einstein College of Medicine

Residency, Internal Medicine, Mount Sinai Hospital

Residency, Hospital Medicine, Mount Sinai Hospital

Fellowship, Hematology & Oncology, Mount Sinai Hospital

Publications

128

Publications

Selected Publications

HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosis: CHRONIC MYELOPROLIFERATIVE NEOPLASMS. Shivani Handa, Christoph Schaniel, Joseph Tripodi, Daiva Ahire, Md Babu Mia, Sophie Klingborg, Douglas Tremblay, Bridget K. Marcellino, Ronald Hoffman, Vesna Najfeld. Leukemia

Diagnosis and Treatment of Polycythemia Vera: A Review. Douglas Tremblay, Marina Kremyanskaya, John Mascarenhas, Ronald Hoffman. JAMA - Journal of the American Medical Association

Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study: MYELODYSPLASTIC NEOPLASM. Douglas Tremblay, Clifford Csizmar, Courtney D. DiNardo, Somedeb Ball, Noa Rippel, Danielle Hammond, Tapan M. Kadia, Farhad Ravandi, Kelly Chien, Grace Van Hyfte, Madhu Mazumdar, Antoine Saliba, Abhishek Mangaonkar, Terra Lasho, Aref Al-Kali, Marina Kremyanskaya, Jonathan Feld, Lewis R. Silverman, Rami Komrokji, John Mascarenhas, Eric Padron, Guillermo Garcia-Manero, David A. Sallman, Mrinal M. Patnaik, Guillermo Montalban-Bravo. Leukemia

View All Publications

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Tremblay during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

PharmaEssentia

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Tremblay during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

PharmaEssentia

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.